- Home
- HYFM vs ERNA Comparison
HYFM vs ERNA Comparison
Compare HYFM & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYFM | ERNA |
|---|---|---|
| Founded | 1977 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 10.2M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | HYFM | ERNA |
|---|---|---|
| Price | $1.73 | $1.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.4K | ★ 47.9K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,443,000.00 | $1,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.50 | $1.09 |
| 52 Week High | $7.50 | $14.40 |
Technical Indicators
Market Signals| Indicator | HYFM | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.48 | 49.26 |
| Support Level | $1.70 | $1.10 |
| Resistance Level | $2.00 | $1.43 |
| Average True Range (ATR) | 0.15 | 0.10 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 36.89 | 70.96 |
Price Performance
Historical ComparisonAbout HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.